Get connected. Stay Informed.

Receive free updates and exclusive offers.

Stay up-to-date with the treatment that could make all the difference for dogs with osteoarthritis.






Indications
Adequan® Canine is recommended for intramuscular injection for the control of signs associated with non-infectious degenerative and/or traumatic arthritis of canine synovial joints.
Important Safety Information
Adequan® Canine should not be used in dogs who are hypersensitive to PSGAG or who have a known or suspected bleeding disorder. It should be used with caution in dogs with renal or hepatic impairment. Adverse reactions in clinical studies (transient pain at injection site, transient diarrhea, and abnormal bleeding) were mild and self-limiting. In post approval experience, death has been reported in some cases; vomiting, anorexia, depression/lethargy and diarrhea have also been reported. The safe use of PSGAG in breeding, pregnant or lactating dogs has not been evaluated. For additional safety information, please see Full Prescribing Information.
*The exact mechanism of action in dogs is not known.
1. Adequan® Canine Prescribing Information, Rev. 1/18.
2. Adequan® Canine (polysulfated glycosaminoglycan) NADA 141-038 Freedom of Information Summary, 1997.

Adequan® and the Dog Head design are registered trademarks of Luitpold Pharmaceuticals, Inc.
© 2018 Luitpold Animal Health, a division of Luitpold Pharmaceuticals, Inc.
PP-AC-US-0004 4/2018
Click here to learn how Adequan® may also help horses with Degenerative Joint Disease (DJD).








Adequan® and the Dog Head design are registered trademarks of Luitpold Pharmaceuticals, Inc.
One Luitpold Drive, PO Box 9001, Shirley, NY 11967   |   800-458-0163   |   info@adequancanine.com
© 2018 Luitpold Animal Health, a division of Luitpold Pharmaceuticals, Inc.     PP-AC-US-0004 (v3.0) 4/2018